| ARID1A mutations in endometriosis-associated ovarian carcinomas KC Wiegand, SP Shah, OM Al-Agha, Y Zhao, K Tse, T Zeng, J Senz, ... New England Journal of Medicine 363 (16), 1532-1543, 2010 | 1889 | 2010 |
| Mutation of FOXL2 in granulosa-cell tumors of the ovary SP Shah, M Köbel, J Senz, RD Morin, BA Clarke, KC Wiegand, G Leung, ... New England Journal of Medicine 360 (26), 2719-2729, 2009 | 851 | 2009 |
| Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1/anti-CTLA-4 combined therapy TN Gide, C Quek, AM Menzies, AT Tasker, P Shang, J Holst, J Madore, ... Cancer cell 35 (2), 238-255. e6, 2019 | 617 | 2019 |
| Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study W Sieh, M Köbel, TA Longacre, DD Bowtell, A DeFazio, MT Goodman, ... The lancet oncology 14 (9), 853-862, 2013 | 457 | 2013 |
| PD‐L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti‐PD‐1/PD‐L 1 clinical trials J Madore, RE Vilain, AM Menzies, H Kakavand, JS Wilmott, J Hyman, ... Pigment cell & melanoma research 28 (3), 245-253, 2015 | 437 | 2015 |
| CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti … J Edwards, JS Wilmott, J Madore, TN Gide, C Quek, A Tasker, A Ferguson, ... Clinical Cancer Research 24 (13), 3036-3045, 2018 | 348 | 2018 |
| UV-associated mutations underlie the etiology of MCV-negative Merkel cell carcinomas SQ Wong, K Waldeck, IA Vergara, J Schröder, J Madore, JS Wilmott, ... Cancer research 75 (24), 5228-5234, 2015 | 328 | 2015 |
| PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma WA Cooper, T Tran, RE Vilain, J Madore, CI Selinger, M Kohonen-Corish, ... Lung cancer 89 (2), 181-188, 2015 | 318 | 2015 |
| Programmed death ligand 1 expression in triple‐negative breast cancer is associated with tumour‐infiltrating lymphocytes and improved outcome RK Beckers, CI Selinger, R Vilain, J Madore, JS Wilmott, K Harvey, ... Histopathology 69 (1), 25-34, 2016 | 239 | 2016 |
| Dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in melanoma RE Vilain, AM Menzies, JS Wilmott, H Kakavand, J Madore, A Guminski, ... Clinical Cancer Research 23 (17), 5024-5033, 2017 | 237 | 2017 |
| Targeting CD39 in cancer reveals an extracellular ATP-and inflammasome-driven tumor immunity XY Li, AK Moesta, C Xiao, K Nakamura, M Casey, H Zhang, J Madore, ... Cancer discovery 9 (12), 1754-1773, 2019 | 203 | 2019 |
| MAPK signaling and inflammation link melanoma phenotype switching to induction of CD73 during immunotherapy J Reinhardt, J Landsberg, JL Schmid-Burgk, BB Ramis, T Bald, N Glodde, ... Cancer research 77 (17), 4697-4709, 2017 | 147 | 2017 |
| Tumor suppressor microRNAs contribute to the regulation of PD-L1 expression in malignant pleural mesothelioma SC Kao, YY Cheng, M Williams, MB Kirschner, J Madore, T Lum, ... Journal of Thoracic Oncology 12 (9), 1421-1433, 2017 | 142 | 2017 |
| Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma J Madore, F Ren, A Filali‐Mouhim, L Sanchez, M Köbel, PN Tonin, ... The Journal of Pathology: A Journal of the Pathological Society of Great …, 2010 | 128 | 2010 |
| Recurrent inactivating RASA2 mutations in melanoma R Arafeh, N Qutob, R Emmanuel, A Keren-Paz, J Madore, A Elkahloun, ... Nature genetics 47 (12), 1408-1410, 2015 | 123 | 2015 |
| PD-L1 negative status is associated with lower mutation burden, differential expression of immune-related genes, and worse survival in stage III melanoma J Madore, D Strbenac, R Vilain, AM Menzies, JYH Yang, JF Thompson, ... Clinical Cancer Research 22 (15), 3915-3923, 2016 | 110 | 2016 |
| Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancer F Al-Ejeh, PT Simpson, JM Sanus, K Klein, M Kalimutho, W Shi, ... Oncogenesis 3 (4), e100-e100, 2014 | 109 | 2014 |
| H3K27 demethylation by JMJD3 at a poised enhancer of anti‐apoptotic gene BCL2 determines ERα ligand dependency A Svotelis, S Bianco, J Madore, G Huppé, A Nordell‐Markovits, ... The EMBO journal 30 (19), 3947-3961, 2011 | 106 | 2011 |
| BTN3A2 expression in epithelial ovarian cancer is associated with higher tumor infiltrating T cells and a better prognosis C Le Page, A Marineau, PK Bonza, K Rahimi, L Cyr, I Labouba, J Madore, ... Plos one 7 (6), e38541, 2012 | 105 | 2012 |
| A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma KAW Wadt, LG Aoude, P Johansson, A Solinas, A Pritchard, O Crainic, ... Clinical genetics 88 (3), 267-272, 2015 | 99 | 2015 |
